ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

• TACSI Trial: Dual or Single Antiplatelet Therapy After CABG in Patients With ACS

  In the TACSI trial, researchers evaluated ticagrelor plus aspirin versus aspirin alone in about 2,200 patients who underwent coronary artery bypass grafting (CABG) for acute coronary syndrome (ACS). At 12 months, dual antiplatelet therapy (DAPT) did not reduce major adverse cardiac events compared to aspirin alone. However, it was associated with a higher risk of major bleeding. These findings do not support routine DAPT use post-CABG in ACS patients, though longer-term follow-up is still needed.   In this interview, Drs. Steven E. Nissen and Anders Jeppsson discuss "TACSI Trial: Dual or Single Antiplatelet Therapy After CABG in Patients With ACS".   SUGGESTED MATERIALS:  Jeppsson A, James S, Moller CH, et al. Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome. N Engl J Med. Published online September 1, 2025. doi:10.1056/NEJMoa2508026   TACSI: Dual or single antiplatelet therapy after CABG in patients with acute coronary syndrome: Reported from ESC Congress 2025 (PCRonline website). 2025. Available at: https://www.pcronline.com/News/Whats-new-on-PCRonline/2025/ESC/TACSI-Dual-or-single-antiplatelet-therapy-after-CABG-in-patients-with-acute-coronary-syndrome. Accessed 10/31/25.   Subscribe to ACCEL 

  --------  

  9:11

  --------

  9:11
• VICTORION-Difference: Inclisiran-Based Strategy vs. Standard of Care

  Current clinical challenges in lipid control include achieving and maintaining target LDL-cholesterol levels in patients at high risk for atherosclerotic cardiovascular disease, especially those who do not respond adequately to standard therapies. The VICTORION-Difference trial demonstrated that an inclisiran-based treatment strategy significantly outperformed usual care in helping patients reach early and sustained LDL-C goals. This approach also resulted in fewer muscle-related side effects, a common barrier to adherence. Inclisiran offers a convenient, effective, and well-tolerated option for improving lipid management in these patients.    In this interview, Drs. Kim A. Williams and Ulf Landmesser discuss "VICTORION-Difference: Inclisiran-Based Strategy vs. Standard of Care."   Subscribe to ACCEL 

  --------  

  12:50

  --------

  12:50
• Aortopathies: What A Cardiologist Needs to Know

  What if your genes could predict a life-threatening condition before symptoms ever appear? Explore how medical science uncovered the genetic roots of thoracic aortic aneurysm—and why that discovery changed everything. From famous historical figures to modern patients, the implications are profound: understanding the exact genetic mutation can guide treatment and safeguard entire families.   In this interview, Drs. Jeroen J. Bax and John A. Elefteriades discuss "Aortopathies: What A Cardiologist Needs to Know".   Subscribe to ACCEL 

  --------  

  17:36

  --------

  17:36
• PhysioSync-HF: Conduction System vs. Biventricular Pacing in Cardiac Resynchronization in HFrEF

  Can a newer, more targeted pacing method revolutionize heart failure treatment? The PhysioSync-HF trial investigates conduction system pacing as a potentially more effective and affordable alternative to traditional cardiac resynchronization therapy. Explore the surprising differences between this study and prior research and hear firsthand what it was like to lead a nationwide, publicly funded clinical trial across Brazil. This episode dives deep into innovation, equity, and the future of heart care.  In this interview, Drs. Joseph Marine and André Zimerman discuss "PhysioSync-HF: Conduction System vs. Biventricular Pacing in Cardiac Resynchronization in HFrEF".   Subscribe to ACCEL 

  --------  

  12:36

  --------

  12:36
• DAPT-SHOCK-AMI Trial: Cangrelor in Cardiogenic Shock

  The DAPT SHOCK AMI trial is the first major study to evaluate antiplatelet therapy specifically in patients with cardiogenic shock (CS) following acute myocardial infarction (AMI). It compares initial treatment strategies using cangrelor versus crushed ticagrelor. Early and potent platelet inhibition is critical for restoring microvascular reperfusion in this high-risk population. Previous randomized trials have excluded these patients, leaving a gap in evidence for optimal antiplatelet management in AMI-CS.    In this interview, Drs. Dipti Itchhaporia and Zuzana Motovska discuss "DAPT-SHOCK-AMI Trial: Cangrelor in Cardiogenic Shock".  Subscribe to ACCEL 

  --------  

  10:57

  --------

  10:57

More Education podcasts

Trending Education podcasts

About ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research: Podcasts in Family